| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of US$ 600/kg
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| product name | Apixaban |
| CAS NO. | 503612-47-3 |
| Specification | 99% |
| Appearance | white powder |
| Package | 1KG/Bag,25Kg/drum |
| MOQ | 1Kg |
The chemical name of apixaban is 1-(4-methoxyphenyl)-7-oxo-6[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide, with a molecular formula of C25H25N5O4, a molecular weight of 459.49700, a density of 1.42g/cm3, a boiling point of 770.468ºC at 760 mmHg, a flash point of 419.764ºC, and a refractive index of 1.705. It is clinically used for adult patients undergoing elective hip or knee replacement to prevent venous thromboembolic events (VTE).
Dosage and Administration
The recommended dose of this product is 2.5 mg each time, taken orally twice a day, with water, and not affected by meals. The first dose should be between 12 and 24 hours after surgery. When deciding the specific time to take the drug in this time window, the doctor needs to consider both the potential benefits of early anticoagulation to prevent VTE and the risk of postoperative bleeding.
For patients undergoing hip replacement: The recommended course of treatment is 32 to 38 days
For patients undergoing knee replacement: The recommended course of treatment is 10 to 14 days
| Items | Standards | Results |
| Appearance | white powder | Complies |
| Specification | 99% | 99.20% |
| Loss on Drying | ≤ 5.0% | Complies |
| Heavy Metal | ≤ 10.0 mg/kg | Complies |
| Pb | ≤ 2.0 mg/kg | Complies |
| As | ≤ 1.0 mg/kg | Complies |
| Hg | ≤ 0.1 mg/kg | Complies |
| Total Plate Count | ≤ 1000cfu/g | Complies |
| Yeast&Mold | ≤ 100cfu/g | Complies |
| E.coil | Negative | Negative |
| Salmonella | Negative | Negative |
| Conclusion: in conformity with the enterprise standard | ||
In 2007, Bristol-Myers Squibb formally implemented a global strategic cooperation agreement to jointly develop and sell the anticoagulant product apixaban; in 2011, it was first approved in the 27 EU countries, Iceland and Norway for the prevention of venous thrombosis in adult patients undergoing elective hip or knee replacement surgery; in January 2013, it obtained the import drug license issued by the China Food and Drug Administration for use in adult patients undergoing elective hip or knee replacement surgery to prevent venous thromboembolic events (VTE), and then officially launched in China in April 2013.
Apixaban is a new oral anticoagulant, a new oral factor Xa inhibitor, and a drug used to prevent and treat thrombosis.
The recommended dose is 2.5 mg, taken orally twice a day, which effectively prevents venous thromboembolism without increasing the risk of bleeding, and does not require routine monitoring of coagulation function or dose adjustment.
The drug is used to prevent venous thromboembolism (VTE) events in adult patients undergoing elective hip or knee replacement surgery.
){kind=link}